首页> 外文期刊>International journal of oncology >The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells
【24h】

The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells

机译:腺苷介导的lncRNA MEG3活化的机制及其在人肝癌细胞中的抗肿瘤作用

获取原文
           

摘要

Long non-coding RNA MEG3 is suggested to function as a tumor suppressor. However, the activation mechanism of MEG3 is still not well understood and data are not available on its role under adenosine-induced apoptosis. In this study, HepG2 cells were treated with adenosine or 5-Aza?cdR. Methylation status of MEG3 promoter was detected by methylation specific PCR (MSP) and MEG3 expression was determined by qRT-PCR. PcDNA3.1-MEG3 recombinant plasmid was constructed and transfected to hepatoma HepG2 and Huh7 cells. Cell growth, morphological changes, cell-cycle distribution and apoptosis were analyzed by MTT assay, fluorescence microscopy and flow cytometry. The mRNA and protein expression levels were detected by qRT-PCR and western blot analysis. MEG3 binding proteins were screened by the improved MS2 biotin tagged RNA affinity purification method. The co-expression network of MEG3 was generated by GO analysis and ILF3 was identified as MEG3 binding protein by RNA pulldown and western blot analysis. Both adenosine and 5-Aza-CdR increased MEG3 mRNA expression and the CpG island of MEG3 gene in HepG2 cells was typical hypermethylation. Ectopic expression of MEG3 inhibited hepatoma cell growth in a time-dependent manner, resulted in cell cycle arrest and induced apoptosis. Ectopic expression of MEG3 increased p53, caspase-3 mRNA and protein levels, decreased MDM2 and cyclin?D1 mRNA and protein levels, as well as ILF3 protein expression in HepG2 cells. These findings are the first to identify that adenosine increases MEG3 expression by inhibition of DNA methylation and its antitumor effects is involved in MEG3 activation. ILF3 may participate in the anticancer regulation of MEG3 by interacting with MEG3.
机译:建议将长的非编码RNA MEG3用作肿瘤抑制物。然而,MEG3的激活机制仍不甚为人所知,在腺苷诱导的细胞凋亡下其作用的数据尚无。在这项研究中,HepG2细胞用腺苷或5-Aza?cdR处理。通过甲基化特异性PCR(MSP)检测MEG3启动子的甲基化状态,并通过qRT-PCR确定MEG3表达。构建了PcDNA3.1-MEG3重组质粒,并将其转染到肝癌HepG2和Huh7细胞中。通过MTT分析,荧光显微镜和流式细胞术分析细胞生长,形态变化,细胞周期分布和凋亡。通过qRT-PCR和蛋白质印迹分析检测mRNA和蛋白质表达水平。通过改进的MS2生物素标记的RNA亲和纯化方法筛选MEG3结合蛋白。通过GO分析产生MEG3的共表达网络,并且通过RNA下拉和蛋白质印迹分析将ILF3鉴定为MEG3结合蛋白。腺苷和5-Aza-CdR均可增加MEG3 mRNA的表达,并且HepG2细胞中MEG3基因的CpG岛是典型的高甲基化。 MEG3的异位表达以时间依赖性方式抑制肝癌细胞的生长,导致细胞周期停滞并诱导凋亡。 MEG3的异位表达增加了HepG2细胞中p53,caspase-3 mRNA和蛋白的水平,MDM2和cyclin?D1 mRNA和蛋白的水平降低以及ILF3蛋白的表达。这些发现是第一个鉴定腺苷通过抑制DNA甲基化增加MEG3表达的方法,并且其抗肿瘤作用与MEG3激活有关。 ILF3可能通过与MEG3相互作用而参与MEG3的抗癌调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号